ArticleFrontiers in immunology2024

Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced HCC.

Zhenyun Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.